Sugi Predict

Sugi Predict / Compounds / SCHEMBL3568679

SCHEMBL3568679

SCHEMBL3568679

CN1CCN(S(=O)(=O)c2cc[c]cc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.68
▸ ATM Q13315 1/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ USP2 O75604 1/20 0.62
▸ TSHR P16473 4/20 0.60
▸ KMT2A Q03164 2/20 0.58
▸ APOBEC3A P31941 2/20 0.58
▸ APOBEC3G Q9HC16 2/20 0.58
▸ HTT P42858 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ LMNA P02545 1/20 0.58
▸ CASP1 P29466 1/20 0.54
▸ CASP7 P55210 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1229961 0.82 USP2 (0.69) POLBSMN1; SMN2USP2TSHRKMT2A
SCHEMBL421626 0.82 USP2 (0.63) POLBUSP2TSHRKMT2AAPOBEC3A
SCHEMBL76639 0.81 USP2 (0.73) POLBSMN1; SMN2USP2TSHRKMT2A
SCHEMBL2122633 0.81 USP2 (0.73) POLBSMN1; SMN2USP2TSHRKMT2A
SCHEMBL3936569 0.81 POLB (1.00) POLBATMSMN1; SMN2USP2TSHR
SCHEMBL1419404 0.80 POLB (0.65) POLBATMSMN1; SMN2USP2TSHR
SCHEMBL7564728 0.79 KMT2A (0.84) POLBATMSMN1; SMN2USP2TSHR
SCHEMBL9386579 0.79 KMT2A (0.84) POLBATMSMN1; SMN2USP2TSHR
SCHEMBL8200020 0.79 KMT2A (0.84) POLBATMSMN1; SMN2USP2TSHR
SCHEMBL5656838 0.79 USP2 (0.44) POLBATMSMN1; SMN2USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 — — US claimed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 — — US claimed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 — — EP claimed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 — — EP claimed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 — — WO claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 — — US claimed
US-7705023-B2 Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2010-04-27 — — US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 — — US disclosed
EP-1778632-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2008-08-20 — — EP disclosed
CN-100372532-C Imidazolin-2-ylaminophenyl amides as IP antagonists. HOFFMANN LA ROCHE (CH) 2008-03-05 — — CN disclosed
WO-2008001134-A1 1,2,3,8,9,9A-HEXAHYDRO-7H-BENZO(DE)-1,7-NAPHTHYRIDIN-7-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-01-03 — — WO disclosed
US-20070287715-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2007-12-13 — — US disclosed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 — — US disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 — — US disclosed
US-6998414-B2 Substituted arylamides as IP antagonists ROCHE PALO ALTO LLC (US) 2006-02-14 — — US disclosed
EP-1622611-A1 IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-02-08 — — EP disclosed
US-20060004075-A1 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC 2006-01-05 — — US disclosed
WO-2005123673-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2005-12-29 — — WO disclosed
WO-2004096213-A1 IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-11 — — WO disclosed
US-20040220247-A1 Substituted arylamides as IP antagonists ROCHE PALO ALTO LLC 2004-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 POLB 3511/4885ATM 784/4885SMN1; SMN2 2035/4885
US-20060004075-A1 Substituted aryl amides as IP antagonists INSR, INSRR, GIPR POLB 3689/4885ATM 3338/4885SMN1; SMN2 4654/4885
US-20070287715-A1 Indoles Useful in the Treatment of Inflammation PTGS1, IDO1, PTGES POLB 3550/4885ATM 3830/4885SMN1; SMN2 4318/4885
US-20040220247-A1 Substituted arylamides as IP antagonists INSR, PTGER1, INSRR POLB 3937/4885ATM 4362/4885SMN1; SMN2 4060/4885
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 POLB 3766/4885ATM 4814/4885SMN1; SMN2 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.